Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors selectively induce cell death in human glioblastoma stem cells: Perspectives for preventing glioblastoma recurrence

Glioblastoma recurrence, largely driven by chemo- and radiotherapy-resistant glioma stem cells, remains a major clinical obstacle. Although nicotinamide phosphoribosyltransferase is key to cancer metabolism, past clinical trials with systemic inhibitors failed due to severe toxicity and limited efficacy against the bulk tumor mass. This study investigates whether nicotinamide phosphoribosyltransferase targeting can be repurposed, shifting the focus from reducing primary tumor size to selectively eliminating patient-derived glioblastoma stem cells to prevent relapses. Methods We assessed nicotinamide phosphoribosyltransferase expression and metabolic dependence in patient-derived glioblastoma stem cells, standard glioblastoma cell lines, and non-malignant human cells (astrocytes, endothelial cells, and differentiated neurons). Cytotoxicity, apoptosis, and therapeutic selectivity of small-molecule inhibitors were analyzed alongside enzyme-silencing experiments. Results Patient-derived glioblastoma stem cells showed high nicotinamide phosphoribosyltransferase levels together with negligible nicotinate phosphoribosyltransferase expression, making them strictly dependent on the salvage pathway. Synthetic nicotinamide phosphoribosyltransferase inhibitors induced apoptosis in glioblastoma stem cells at nanomolar or picomolar concentrations, whereas non-malignant neural and vascular cells tolerated doses up to the micromolar range. Standard glioblastoma cell lines were considerably less sensitive, failing to reflect stem cell responses. Finally, genetic silencing of nicotinamide phosphoribosyltransferase mimicked inhibitor-induced toxicity, confirming target-specific action. Conclusion These results reveal a clear therapeutic window for nicotinamide phosphoribosyltransferase inhibitors. Instead of broad systemic use against primary tumors, these agents could serve as targeted post-operative tools to eradicate residual stem cells and reduce the risk of glioblastoma recurrence.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2026-11-19
DOI
https://doi.org/10.1016/j.biopha.2026.120050
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors selectively induce cell death in human glioblastoma stem cells: Perspectives for preventing glioblastoma recurrence

Mayra Paolillo, Cristina Lanni, Cabras Paolo, Marco Peviani et al.
Biomedicine & Pharmacotherapy
Glioma Diagnosis and Treatment
article

Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors selectively induce cell death in human glioblastoma stem cells: Perspectives for preventing glioblastoma recurrence

Mayra Paolillo, Cristina Lanni, Cabras Paolo, Marco Peviani, Francesco Raimondi, Cristina Travelli, Ubaldina Galli, Daniela Buonocore, Alessia Buccellini
article en

Abstract

Glioblastoma recurrence, largely driven by chemo- and radiotherapy-resistant glioma stem cells, remains a major clinical obstacle. Although nicotinamide phosphoribosyltransferase is key to cancer metabolism, past clinical trials with systemic inhibitors failed due to severe toxicity and limited efficacy against the bulk tumor mass. This study investigates whether nicotinamide phosphoribosyltransferase targeting can be repurposed, shifting the focus from reducing primary tumor size to selectively eliminating patient-derived glioblastoma stem cells to prevent relapses. Methods We assessed nicotinamide phosphoribosyltransferase expression and metabolic dependence in patient-derived glioblastoma stem cells, standard glioblastoma cell lines, and non-malignant human cells (astrocytes, endothelial cells, and differentiated neurons). Cytotoxicity, apoptosis, and therapeutic selectivity of small-molecule inhibitors were analyzed alongside enzyme-silencing experiments. Results Patient-derived glioblastoma stem cells showed high nicotinamide phosphoribosyltransferase levels together with negligible nicotinate phosphoribosyltransferase expression, making them strictly dependent on the salvage pathway. Synthetic nicotinamide phosphoribosyltransferase inhibitors induced apoptosis in glioblastoma stem cells at nanomolar or picomolar concentrations, whereas non-malignant neural and vascular cells tolerated doses up to the micromolar range. Standard glioblastoma cell lines were considerably less sensitive, failing to reflect stem cell responses. Finally, genetic silencing of nicotinamide phosphoribosyltransferase mimicked inhibitor-induced toxicity, confirming target-specific action. Conclusion These results reveal a clear therapeutic window for nicotinamide phosphoribosyltransferase inhibitors. Instead of broad systemic use against primary tumors, these agents could serve as targeted post-operative tools to eradicate residual stem cells and reduce the risk of glioblastoma recurrence.

Biomedicine & PharmacotherapyVol. 205
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), Scuola Normale Superiore (IT), University of Pavia (IT)
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon